Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome
This case series reported survival, response, and safety outcomes for patients with mycosis fungoides or Sézary syndrome who received pembrolizumab at a single institution.
Authors
- Jordan S. Carter (ORCID: https://orcid.org/0000-0003-1353-7766)
- Jakub Svoboda (ORCID: https://orcid.org/0000-0002-6359-7065)
- Jonathan Sussman (ORCID: https://orcid.org/0000-0002-7702-8816)
- Elise A. Chong (ORCID: https://orcid.org/0000-0001-8895-1625)
- Stefan Klaus Barta (ORCID: https://orcid.org/0000-0002-3280-5271)
- Jina Chung (ORCID: https://orcid.org/0000-0001-9140-7815)
- Austin Yang
- Daniel J. Landsburg (ORCID: https://orcid.org/0000-0002-5077-4181)
- Monica Chelius
- Michael J. LaRiviere (ORCID: https://orcid.org/0000-0002-1662-5086)
- Harper Hubbeling (ORCID: https://orcid.org/0000-0003-4812-5235)
- Alain H. Rook (ORCID: https://orcid.org/0000-0002-8356-0569)
- Omar Elghawy (ORCID: https://orcid.org/0000-0002-0786-8035)
- Stephen J. Schuster (ORCID: https://orcid.org/0000-0002-3376-8978)
- Sunita D. Nasta (ORCID: https://orcid.org/0000-0002-8981-2931)
- John P. Plastaras (ORCID: https://orcid.org/0000-0002-4916-9857)
- Ellen Kim (ORCID: https://orcid.org/0000-0001-9379-0192)
- Colin Thomas
Institutions
- UPMC Hillman Cancer Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1001/jamadermatol.2025.0251
- Citations
- 1
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 2.00